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A B S T R A C T
Bidirectional interactions exist between the kidneys and the gut. These interactions are commonly referred to as
the gut-kidney axis. Chronic kidney disease (CKD) leads to disturbances of the gut ecosystem. Key features
include the increase of protein fermentation at the expense of carbohydrate fermentation and a disrupted epi-
thelial barrier. A disturbed gut ecosystem may contribute to the high burden of cardiovascular disease in patients
with CKD. The present review discusses the impact of CKD on the gut microenvironment and provides an update
as to how gut dysbiosis and a leaky gut may be linked to accelerated cardiovascular disease and hypertension.
1. Gut microbiota in CKD
The human intestinal tract, and especially the large intestine, is
colonized by trillions of microorganisms. These microorganisms encode
at least 150-fold more genes than the human genome. The combined
genetic potential of the endogenous ﬂora is referred to as the ‘micro-
biome’ [1]. The composition of the microbial communities shows huge
inter-individual variation. This variation is driven by host factors as
well as environmental inﬂuences [1]. Although the microbiota is ex-
posed to a continuously changing environment, its composition and
function in an individual are stable against perturbations [2]. The mi-
crobiome provides the host with enhanced metabolic capabilities,
protection against pathogens, education of the immune system, and
modulation of gastrointestinal development[3].
Several chronic disabilities, including obesity and inﬂammatory
bowel disease [4,5], have been documented to go along with profound
changes of the intestinal microbiota composition. The impact of chronic
kidney disease (CKD) on the gut microbiome has only been explored in
recent years. Vaziri et al. studied the microbial composition in stool
samples and observed marked diﬀerences in the abundance of 190
bacterial operational taxonomic units (OTUs) between the end stage
renal disease (ESRD) and control groups [6]. These ﬁndings were re-
cently conﬁrmed in a cohort of Chinese ESRD patients. The absolute
quantiﬁcation of total bacteria was signiﬁcantly reduced, while di-
versity at the phylum level was maintained [7].
It should be emphasized that the renal phenotype is much broader
than the loss of kidney function, as almost all patients in ESRD are on a
multidrug regimen, are exposed to the eﬀects of extracorporeal treat-
ments and are prescribed dietary restrictions. Testing the isolated eﬀect
of the loss of kidney function on microbiome composition is only pos-
sible in experimental models. In several studies exploring the eﬀects of
surgically induced CKD in rats, total richness was reduced in CKD and
the microbial community was diﬀerentially structured [6,8]. Andersen
et al. performed a similar analysis in collagen type IV α3–deﬁcient mice
with Alport syndrome–related progressive CKD. Noteworthy and op-
posite to ﬁndings in the Chinese patient cohort, they observed a higher
amount of colony forming units per gram of feces. Again, they observed
diﬀerentially structured communities, with changes in the class of
Bacteroidales, Burholderiales (family of Alcaligenaceae), Enterobacteriales,
and Verrucomicrobiales [9].
In aggregate, these studies show that ESRD promotes alterations in
the composition of the gut microbiota. This is commonly referred to as
dysbiosis. At present, uncertainties remain as to the underlying patho-
physiology.
2. Gut microbial metabolism in CKD
The gut microbial metabolism provides a signiﬁcant and unique
contribution towards the human metabolome [3]. The gut microbial
metabolism is complex and only partly dependent on gut microbial
composition. Indeed, despite variation in community structure, the
metagenomic carriage of metabolic pathways has been shown to be
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stable, at least among healthy individuals [10].
It is generally accepted that carbohydrate and nitrogen availability
is the most important determinant of colonic microbial metabolism.
Dietary ﬁber composes the main carbohydrate supply in the colon.
Other sources include oligosaccharides and a variety of sugars and non-
absorbable sugar alcohols [11,12]. Nitrogen is provided to the large
intestine from exogenous dietary proteins that escaped digestion in the
small intestine, endogenous proteins and from blood urea that has
diﬀused into the intestinal lumen [13]. The colonic handling of α-
amino nitrogen (amino acids and intermediates) largely depends on the
amount of energy available for bacterial growth and cell division. This
energy mainly results from carbohydrate fermentation. Abundancy of
carbohydrates promotes expansion of the bacterial biomass, requiring
incorporation of α-amino nitrogen. In case of carbohydrate deprivation,
α-amino nitrogen is predominantly fermented, generating potentially
toxic end-products such as phenols and indoles.
The ratio of available carbohydrate to nitrogen progressively de-
clines from proximal to distal colon, aﬀecting regional bacterial com-
position and metabolism [14,15]. Slowing down colonic transit times
may induce upstream expansion of proteolytic species, as a larger part
of the colon will become deprived of carbohydrates, and this may result
in increased generation of bacterial toxins. In a landmark study by
Cummings et al., the urinary excretion rate of phenols was found to be
related mainly to the colonic transit time as well as to the dietary
protein intake [16].
Nutrient intake diﬀers substantially between healthy individuals
and patients with CKD, especially those with ESRD. Dietary re-
commendations in CKD may include restricted intake of potassium,
sodium, phosphate and/or (animal) protein restriction. Such diets are
low in fruit and vegetables and thus low in fermentable carbohydrates
[17]. Also, the colonic transit time is prolonged in many patients with
CKD. Constipation has been reported in>50% of patients on HD and in
up to 29% of patients treated with continuous ambulatory peritoneal
dialysis (CAPD). These prevalences are substantial higher than reported
in healthy persons (10–20%) [18,19]. As a consequence of the changes
in diet and colonic transit time, microbial metabolism moves towards a
predominantly proteolytic fermentation pattern. This metabolic shift
aligns with the data from a metagenomics analysis on stool samples
from patients with ESRD showing a signiﬁcant expansion of bacterial
families possessing urease, uricase, and indole and p-cresol forming
enzymes, and contraction of families possessing butyrate-forming en-
zymes (e.g. Roseburiae, Faecalibacterium prausnitzii, Lactobacillaceae and
Prevotellaceae) [20,21].
The intestinal microbial metabolism is diﬃcult to study in situ.
Using a metabolomic approach, we observed major diﬀerences between
patients treated with HD and healthy individuals. At least part of the
observed diﬀerences could be attributed to diﬀerences in nutrient in-
take, as the fecal microbial metabolite proﬁle of patients closely re-
sembled that of household contacts following the same dietary re-
strictions [22]. As discussed earlier, experimental models of CKD can be
used to separately study the eﬀect of loss of kidney function on the gut
microbial metabolism, irrespective from other aspects of the renal
phenotype. In a 5/6th nephrectomy model in rat, signiﬁcant alterations
in the gut metabolites were found, including reduced abundancy of the
short-chain fatty acid propanoic (also known as proprionic) acid [22].
Similar ﬁndings were noted in an adenine-induced mouse model of
CKD, in which production of both propionic acid and butyric acid was
reduced [23].
Mishima et al. recently studied the metabolic ﬁngerprint in an
adenine-induced mouse model of CKD, and thereby compared germ-
free and speciﬁc pathogen free animals with conventional animals [23].
Using this elegant double-variable experimental model these in-
vestigators were able to determine the origin of the metabolites: diet,
mammalian or microbial metabolism. Several protein-fermentation
metabolites including indoxyl sulphate (IndS), p-cresyl sulphate (PCS),
phenyl sulphate, cholate and hippurate all were shown to originate
exclusively from microbial metabolism [23].
In summary, current evidence suggests that CKD may shift microbial
metabolism towards a predominantly proteolytic fermentation pattern.
The clinical observation of 24h-urinary excretion of p-cresol paralleling
renal function deterioration, supports the notion of CKD being a state of
increased protein fermentation [24].
3. Intestinal barrier in CKD
The intestinal barrier is the master regulator, separating self from
non-self, and coordinating all interactions between the gut microbiome
and human physiology [25].
To prevent paracellular ﬂux of luminal solutes, the intestinal epi-
thelial cells are sealed together by apical junctional complexes, con-
sisting of the tight junction, which is the most luminal component of the
complex, and the subjacent adherens junction. The tight junction is
selectively permeable and is able to discriminate between solutes on the
basis of size and charge. While most research has focused on intestinal
transcellular transport [26], recent advances in the understanding of
the apical junctional complex and tight junction underpin the im-
portance of the paracellular intestinal transport in health and in dis-
ease.
It has been known for a long time that the intestinal barrier function
is impaired in CKD [27]. Only recently, the mechanisms underlying the
increased intestinal permeability have been (partially) unraveled. Va-
ziri et al. observed intense inﬁltrates of lymphocytes into the lamina
propria of animals with 5/6th nephrectomy induced CKD [28]. Tight
junction disintegration in intestinal epithelial cells has been demon-
strated by some [28], but not all investigators [9]. Whether CKD, si-
milar to dietary changes [29] may cause alterations of the inner colonic
mucus layer, thereby compromising the gut barrier function, remains to
be studied. Uremic serum and plasma increased intestinal permeability
in vitro, suggesting the involvement of a humoral component [30,9].
Both direct toxicity by uremic retention molecules (especially ammo-
niumhydroxide) and butyrate depletion may be involved. Also in-
testinal mucosal ischemia due to splanchnic hypoperfusion (e.g. trig-
gered by intradialytic hypotension) and venous congestion due to heart
failure [31] may be hypothesized to contribute to a disrupted gut epi-
thelial barrier in the setting of CKD. Major mechanisms contributing to
gut dysbiosis and a leaky gut in CKD are illustrated in Fig. 1.
4. Consequences of disturbed gut ecosystem in CKD
4.1. Role of increased protein fermentation
Protein fermentation results in the production of potentially toxic
metabolites such as ammonia, amines, phenols and sulﬁdes. Important
representatives of these metabolites are p-cresol and indole. p-Cresol is
a putrefaction metabolite of tyrosine, while indole is generated by
fermentation of tryptophan. After absorption, the majority of p-cresol
and indole is further metabolised and conjugated to form p-cresylsul-
phate (PCS) and indoxyl sulphate (IndS), respectively. Concentrations
of PCS and IndS increase along the progression of CKD [32–34], both as
a consequence of decreased elimination and increased production [35],
to reach concentration in patients with ESRD are 10–50 fold higher
than in healthy controls. Concentrations of PCS and IndS also rise with
ageing [36].
It has been demonstrated in numerous experimental studies that at
uremic concentrations, PCS and IndS may disturb several biological
processes and confer direct toxicity in various cells and tissues. Multiple
signaling cascades are activated and the generation of intracellular
oxidative stress plays a central role (see Fig. 2). For detailed discussion,
the reader is referred to recent excellent reviews dealing with this topic
[37]. PCS and IndS may induce insulin resistance [38], trigger pre-
mature cellular senescence [39], upregulate DNA methyltransferase
[40], activate the renin angiotensin aldosterone system [41], cause
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endothelial dysfunction [42], promote vascular calciﬁcation [43] and
contribute to left ventricular hypertrophy and diastolic dysfunction.
Toxicity may also be indirect as IndS and PCS, acting as sulphate sinks,
may cause sulphate depletion with inherent risks. Whether uremic
toxins originating from microbial metabolism trigger or sustain a sys-
temic inﬂammatory reaction remains a matter of ongoing controversy.
While PCS was shown to activate leucocyte free radical production
[44], we failed to elicit an inﬂammatory response in monocytes with
either PCS or IndS [45]. Moreover, clinical studies investigating the
relationship between serum levels of uremic toxins originating from
microbial metabolism and markers of inﬂammation so far yielded in-
consistent ﬁndings [46].
In line with the experimental data, circulating levels of PCS and
IndS have been repeatedly associated with cardiovascular morbidity
(ischemic and thrombotic events, atrial ﬁbrillation, arterial stiﬀness
and vascular calciﬁcation) and mortality. Most evidence has been ob-
tained in patients with CKD [33,47,34,48]. However also in individuals
with preserved kidney function, clear associations between PCS and
IndS concentrations and cardiovascular endpoints have been reported.
E.g., in a population-based study, the prevalence of hypertension in-
creased along PCS and IndS quartiles [36]. Increased exposure to PCS
and IndS may be hypothezised to be in the causal pathway between a
diet rich in red meat and poor renal [49] and cardiovascular outcomes.
4.2. Role of decreased carbohydrate fermentation
Colonic carbohydrate fermentation results in the generation of short
chain fatty acids (SCFAs), primarily acetate, propionate, and butyrate.
SCFA production in the mammalian colon approximately reaches
100mM per day [50]. SCFA diﬀuse through the intestinal mucosa,
circulate in the bloodstream (via the portal system; at the low-milli-
molar range), and act on G protein-coupled receptors (GPCR) expressed
at the plasma membrane of target cells distributed widely in the
mammalian organism [51,52]. Various health promoting eﬀects have
been ascribed to speciﬁc SCFAs. They may reduce the risk of developing
gastrointestinal disorders, cancer, and cardiovascular disease. Hence, a
Fig. 1. Pathophysiology and consequences of gut dysbiosis and leaky gut in patients with CKD. Abbreviations: GIT: gastrointestinal tract, CHO: carbohydrate; SCFA:
short chain fatty acid; CVD: cardiovascular disease; PEW: protein energy wasting; CKD: chronic kidney disease.
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growing body of evidence supports that a high blood pressure (BP) is
coupled to depressed carbohydrate fermentation [50]. Prescient ex vivo
studies using pressure myography applied to rodent and human samples
suggested that SCFA induce the vasodilation of resistance vessels in an
endothelium-dependent manner [53–55]. Binding of SCFAs to the
GPCR can activate a variety of intracellular signaling cascades, invol-
ving nuclear transcription, enzyme activation, and cell membrane ion
transport [56]. Interestingly enough, sensory GPCR have been identi-
ﬁed in tissues and organs not directly linked to taste or olfaction, like
the kidney and the cardiovascular system [51,57–59]. Most of these
GPCR are orphan receptors, i.e. with no identiﬁed endogenous ligands
and functions. Still, olfactory receptor 78 (Olfr78) and Gpr41 have been
recently demonstrated to act as receptors for SCFAs, with a putative
role in BP control [56,60,61]. Of note, 2 additional SCFA GPCR are
currently under investigation: Gpr109A (butyrate) and Gpr43 (acetate,
propionate, and butyrate) [56].
At the mRNA level, Gpr41 is expressed in the vascular endothelium
of intact vessels, where it lowers baseline BP by decreasing active
vascular tone [54]. Gpr41-null mice present with hypertension of vas-
cular origin: at baseline, plasma renin concentration is similar in Gpr41
KO and WT mice, and the systolic hypertension in Gpr41 KO mice is not
salt-sensitive [54]. Gpr41 couples to Gi in response to various SCFA,
including propionate, formate, acetate, butyrate and isobutyrate (with
an EC50 in the micromolar range) [62].
Using the LacZ reporter technique, Olfr78 has been located in re-
sistance vessels and in the aﬀerent arteriole in the kidney, which are
physiologically involved in BP regulation [51]. Olfr78 responds to
acetate and propionate, with an EC50 in the millimolar range [51]. In ex
vivo experiments, SCFAs trigger renin secretion from wild-type glo-
meruli, but not from Olfr78-deﬁcient glomeruli. Furthermore, mice
lacking Olfr78 present with lower plasma renin and lower BP [63].
Following i.v. administration of SCFA at the millimolar range, a
rapid dose-dependent drop in BP is observed in mice [63]. In Gpr41-
deﬁcient animals, such a hypotensive response to SCFA infusion is lost.
Conversely, SCFA-induced hypotension is aggravated in Olfr78-null
mice [63]. In toto, these observations suggest that, at least in mouse,
proprionate and acetate modulate the BP diﬀerentially according to the
type of activated receptors: activated Gpr41 causes hypotension,
whereas Olfr78 stimulation favors BP increase [64]. As a reminder,
SCFA EC50 of Gpr41 and Olfr78 signiﬁcantly varies from the micro- to
the millimolar range, respectively, which may partly explain why si-
milar SCFAs target both receptors with opposite BP results. These basic
science data corroborate epidemiological studies showing a signiﬁcant
association between the urinary levels of SCFAs (especially formate)
and BP levels, and reinforce the conclusions of a meta-analysis illus-
trating the inﬂuence of dietary ﬁbers on BP control [65,66]. Further-
more, a meta-analysis of randomized controlled trials showed that the
use of probiotics (which, in turn, increase SCFA production) is asso-
ciated with lower BP levels [67]. Finally, SCFA impact on BP home-
ostasis may also explain why the use of acetate in hemodialysis solu-
tions causes hypotension in patients [68]. Thus, a growing body of
evidence supports that BP regulation is coupled not only to host but also
to microbial metabolism [69]. This conclusion is corroborated by data
from a small study showing an increased Firmicutes/Bacteroidetes ratio
and a decrease in acetate- and butyrate-producing bacteria in hy-
pertensive patients [70]. Furthermore, in hypertensive rats, oral min-
ocycline was able to restore gut microbiota, reduce the Firmicutes/
Bacteroidetes ratio, and attenuate BP levels [70].
Gut dysbiosis may thus be a relevant and so far largely neglected
player in the pathogenesis of hypertension. Besides its putative role in
the pathogenesis of hypertension, SCFA depletion may also contribute
to micro-inﬂammation since SCFAs have been reported to have anti-
inﬂammatory properties by binding Gpr43 [71].
4.3. Role of a disturbed intestinal barrier
Dysfunction of the intestinal barrier in CKD is associated with
bacterial translocation and endotoxinemia, which is related to systemic
inﬂammation, malnutrition, cardiovascular disease, and possibly re-
duced survival [28,72,73,9].
ESRD is associated with micro-inﬂammation, a chronic low-grade
inﬂammatory state that is characterized by elevated levels of circu-
lating pro-inﬂammatory cytokines, including interleukin-6 (IL-6). This
condition has a multifactorial origin involving accumulation of ad-
vanced glycation end-products and oxidized protein products, acidosis,
volume overload, oxidative stress, bio-incompatibility of dialyzer
membrane amongst others. New evidence suggests that a dysfunctional
intestinal barrier may also contribute to the micro-inﬂammatory state
in CKD. An increased intestinal permeability results in the translocation
of bacteria and bacterial cell wall components (endotoxins). This co-
incides with the activation of the immune system as has been demon-
strated in experimental models of CKD [74]. This concept is not new, as
already in 1907, Elie Metchnikoﬀ proposed that chronic systemic in-
ﬂammation may occur as a result of increased permeability and the
Fig. 2. Signaling cascades involved in PCS and IndS mediated cellular toxicity and potential therapeutic approaches. Abbreviations: PTHR1: Parathryoid hormone
receptor 1; AhR: arylhydrocarbon receptor; OAT: organic anion transporter; TF: Tissue factor; HIF: hypoxia inducible factor; Rec Klotho: recombinant Klotho; EMT:
epithelial-to-mesenchymal transition; EGFR: epidermal growth factor receptor.
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escape of bacteria and their products [75]. In line with these data, re-
cent evidence from murine studies indicates that age-associated in-
ﬂammation is at least partly mediated by age-related microbiota in-
creasing intestinal permeability. Systemic inﬂammation in turns
contributes to microbial dysbiosis, thereby initiating a vicious circle
[76].
Actions of endotoxin (lipopolysaccharide) are mediated by inter-
action with the Toll-like receptor 4/MD-2 complex and its co-receptor
CD14 on monocytic cells, initiating an innate immune response and
pro-inﬂammatory signaling. In clinical cohort studies, gut bacterial
translocation and endotoxinemia, directly relates to markers of in-
ﬂammation [77,9].
A growing body of evidence indicates that endotoxinemia and
micro-inﬂammation may be in the causal pathway between CKD and
the high burden of cardiovascular disease [78,72,79–81]. This evi-
dence, in addition, enforces the so-called inﬂammatory hypothesis in
our understanding of the biology of atherosclerosis [82]. Inﬂammatory
cells and signals drive the healing response to vascular injury, allowing
the initiation and growth of atherosclerotic plaque. Inﬂammatory re-
actions probably increase plaque instability and setting up the substrate
for the thrombotic response that causes myocardial damage or infarc-
tion, e.g. by upregulating tissue factor expression. Recent data from a
RCT with canakinumab, a human monoclonal antibody against inter-
leukin-1β, added further credit to the inﬂammatory hypothesis of cor-
onary artery disease [83].
5. Treatment options
A multi-targeted approach may be required to tackle the disturbed
gut ecosystem in CKD. For detailed discussion, the reader is referred to
several excellent reviews discussing this topic in detail [84–86].
5.1. Restoring gut homeostasis
Acknowledging that diet is a key regulator of microbial metabolism,
one may either restrict protein intake or increase dietary ﬁber intake in
an attempt to revert microbial metabolism towards a predominantly
saccharolytic fermentation pattern. As protein restriction is unpalatable
and can accentuate sarcopenia, increasing dietary ﬁber intake provides
a safer and simpler means to restore eubiosis. Fruits and vegetables are
not only rich in dietary ﬁber, but also in potassium, which could be
problematic in patients with advanced CKD. In these patients, pre-
biotics (i.e a non-digestible food ingredient that promotes the growth of
beneﬁcial microorganisms in the intestines) may be an appealing al-
ternative. Other approaches to restore microbial metabolism include
treatment with laxatives (to reduce transit time), probiotics (i.e. live
microorganisms that, when administered in adequate amounts, confer a
health beneﬁt on the host) or genetic manipulation of the colon mi-
crobiota (e.g. to suppress the conversion tryptophan to indole).
5.2. Adsorption of toxic protein fermentation metabolites
Another means to reduce the daily load of potentially toxic end-
products of protein fermentation is to administer sorbents. The oral
charcoal adsorbent AST-120 (Kremezin, Kureha Ltd., Japan) reduces
plasma levels of several end-products of protein fermentation including
IndS and PCS. Animal studies showed beneﬁcial eﬀects on gut [87],
renal and cardiovascular outcomes. Also pilot clinical interventions
studies with AST-120 showed promising results, but renal beneﬁts
could not be conﬁrmed in a large RCT [88]. Characteristics of the study
population and compliance and statistical issues may have contributed
to the negative result of the latter study. Also intake of sevelamer, a
non-calcium, non-aluminum phosphate binder have been associated
with lower PCS levels, but ﬁnding, overall, were inconsistent [89,90].
5.3. Targeting biological activity
The toxicity of PCS and IndS is mediated through various signaling
pathways in which the generation of intracellular oxidative stress and
activation of the aryl hydrocarbon receptor (ahr) play a central role
[37,84]. Organic anion transporters are involved in the intracellular
uptake of IndS and PCS. Fig. 2 summarizes the signaling pathways and
identiﬁes candidate therapeutic targets. The rationale of inhibition of
intracellular uptake and intracellular signal mediators has been de-
monstrated in a series of experimental studies, but clinical eﬃcacy and
safety remain to be demonstrated.
5.4. Increasing the removal of colon-derived toxins
Excretion of IndS, PCS and other microbiome-derived uremic re-
tention solutes is predominantly via the kidneys, as the bile does not
contain signiﬁcant amounts of these solutes (unpublished data). As
these solutes are tightly bound to albumin, glomerular clearance is
limited and most solute is secreted by active transporter systems in the
proximal tubule [91]. Active transport of organic anions is one of the
genetically conserved functions of the kidney. Key transporters include
the organic anion transporter 1 and 3 (OAT 1/3) as well as the organic
anion transporter protein 4C1 (OATP4C1), all of which are facilitated
diﬀusion carriers. Additional transporters include adenosinetripho-
sphate (ATP)-dependent pumps, i.e. P-glycoprotein (P-gp), multidrug
resistance proteins 2 and 4 (MRCP2/4) and breast cancer resistance
protein (BRCP). Theoretically, such systems may be exploited to drive
up the renal excretion of microbiome-derived uremic retention solutes.
In reality, however, due to accumulation of other molecules competing
for the same excretory route, elimination of the microbiome-derived
molecules often is limited by saturation of the transporters.
The strong albumin binding also explains why removal by conven-
tional hemodialysis is limited [92,93]. Alternative treatment regimens
were shown to increase clearances, but their impact on circulating le-
vels, overall, was limited if not negligible. Adsorptive techniques,
though promising from an eﬃcacy point of view, are limited by high
costs and/or non-selective adsorption causing inferring a high risk of
thrombotic complications [94,95].
6. Future directions and conclusions
Over the last decade, it has become clear that the microbiome is
involved in various aspects of the uremic syndrome. Host-microbiota
interactions are bidirectional. The gut microbial composition is altered
in patients with CKD, as is microbial metabolism with a shift towards a
predominant proteolytic fermentation pattern. The intestinal barrier,
shielding the human internal environment from the fascinating world of
microbes, is disturbed in patients with CKD. These alterations con-
tribute via various mechanisms to the high burden of cardiovascular
disease and hypertension in patients with CKD.
The great challenges – however – lie ahead. Although it is becoming
more and more evident that we need to interfere with the disturbed gut
ecosystem in patients with CKD, there are no clear and eﬀective in-
roads. Many questions are still in the open. It is unclear whether we
should primarily interfere with gut microbial composition, gut micro-
bial metabolic activity or both. It is not clear whether it would be
possible to restore a sustained healthy microbiome. It is not even clear
whether patients would beneﬁt most from a healthy normal micro-
biome, or that some alterations, e.g. increased metabolic capacity to
digest urea and uric acid, are necessary adaptations. The time is right to
tackle these challenges, as they hold promise to ﬁnd novel therapeutic
targets for a challenging disease population.
Conﬂict of interest
None of the authors declares a conﬂict of interest.
B. Meijers et al. Pharmacological Research 133 (2018) 101–107
105
References
[1] P.J. Turnbaugh, R.E. Ley, M. Hamady, C.M. Fraser-Liggett, R. Knight, J.I. Gordon,
The human microbiome project, Nature 449 (2007) 804–810.
[2] F. Sommer, J.M. Anderson, R. Bharti, J. Raes, P. Rosenstiel, The resilience of the
intestinal microbiota inﬂuences health and disease, Nat. Rev. Microbiol. 15 (2017)
630–638.
[3] W.R. Wikoﬀ, A.T. Anfora, J. Liu, P.G. Schultz, S.A. Lesley, E.C. Peters, G. Siuzdak,
Metabolomics analysis reveals large eﬀects of gut microﬂora on mammalian blood
metabolites, Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 3698–3703.
[4] V. Tremaroli, F. Backhed, Functional interactions between the gut microbiota and
host metabolism, Nature 489 (2012) 242–249.
[5] M.J. Claesson, I.B. Jeﬀery, S. Conde, S.E. Power, E.M. O'Connor, S. Cusack,
H.M. Harris, M. Coakley, B. Lakshminarayanan, O. O'Sullivan, G.F. Fitzgerald,
J. Deane, M. O'Connor, N. Harnedy, K. O'Connor, D. O'Mahony, Wallace M van SD,
L. Brennan, C. Stanton, J.R. Marchesi, A.P. Fitzgerald, F. Shanahan, C. Hill,
R.P. Ross, P.W. O'Toole, Gut microbiota composition correlates with diet and health
in the elderly, Nature 488 (2012) 178–184.
[6] N.D. Vaziri, J. Wong, M. Pahl, Y.M. Piceno, J. Yuan, T.Z. Desantis, Z. Ni,
T.H. Nguyen, G.L. Andersen, Chronic kidney disease alters intestinal microbial
ﬂora, Kidney Int. (2013) 308–315.
[7] S. Jiang, S. Xie, D. Lv, P. Wang, H. He, T. Zhang, Y. Zhou, Q. Lin, H. Zhou, J. Jiang,
J. Nie, F. Hou, Y. Chen, Alteration of the gut microbiota in Chinese population with
chronic kidney disease, Sci. Rep. 7 (2017) 2870.
[8] M. Kikuchi, M. Ueno, Y. Itoh, W. Suda, M. Hattori, Uremic toxin-producing gut
microbiota in rats with chronic kidney disease, Nephron 135 (2017) 51–60.
[9] K. Andersen, M.S. Kesper, J.A. Marschner, L. Konrad, M. Ryu, V.S. Kumar,
O.P. Kulkarni, S.R. Mulay, S. Romoli, J. Demleitner, P. Schiller, A. Dietrich,
S. Muller, O. Gross, H.J. Ruscheweyh, D.H. Huson, B. Stecher, H.J. Anders,
Intestinal dysbiosis, barrier dysfunction, and bacterial translocation account for
CKD-Related systemic inﬂammation, J. Am. Soc. Nephrol. 28 (2017) 76–83.
[10] Structure, function and diversity of the healthy human microbiome, Nature 486
(2012) 207–214.
[11] A. Birkett, J. Muir, J. Philips, G. Jones, K. O'Dea, Resistant starch lowers fecal
concentrations of ammonia and phenols in humans, Am. J. Clin. Nutr. 63 (1996)
766–772.
[12] E. Smith, G. Macfarlane, Enumeration of human colonic bacteria producing phe-
nolic and indolic compounds: eﬀects of pH, carbohydrate availability and retention
time on dissimilatory aromatic amino acid metabolism, J. Appl. Bact. 81 (1996)
288–302.
[13] P. Evenepoel, B.K. Meijers, B.R. Bammens, K. Verbeke, Uremic toxins originating
from colonic microbial metabolism, Kidney Int. Suppl. (2009) S12–S19.
[14] G.T. Macfarlane, J.H. Cummings, S. Macfarlane, G.R. Gibson, Inﬂuence of retention
time on degradation of pancreatic enzymes by human colonic bacteria grown in a 3-
stage continuous culture system, J. Appl. Bacteriol. 67 (1989) 520–527.
[15] G.T. Macfarlane, S. Macfarlane, Models for intestinal fermentation: association
between food components, delivery systems, bioavailability and functional inter-
actions in the gut, Curr. Opin. Biotechnol. 18 (2007) 156–162.
[16] J. Cummings, M. Hill, E. Bone, W. Branch, D. Jenkins, The eﬀect of meat protein
and dietary ﬁber on colonic function and metabolism, Am. J. Clin. Nutr. 32 (1979)
2094–2101.
[17] B. Meijers, G. Glorieux, R. Poesen, S.J. Bakker, Nonextracorporeal methods for
decreasing uremic solute concentration: a future way to go? Semin. Nephrol. 34
(2014) 228–243.
[18] G. Yasuda, K. Shibata, T. Takizawa, Y. Ikeda, Y. Tokita, S. Umemura, O. Tochikubo,
Prevalence of constipation in continuous ambulatory peritoneal dialysis patients
and comparison with hemodialysis patients, Am. J. Kidney Dis. 39 (2002)
1292–1299.
[19] M.J. Wu, C.S. Chang, C.H. Cheng, C.H. Chen, W.C. Lee, Y.H. Hsu, K.H. Shu,
M.J. Tang, Colonic transit time in long-term dialysis patients, Am. J. Kidney Dis. 44
(2004) 322–327.
[20] J. Wong, Y.M. Piceno, T.Z. Desantis, M. Pahl, G.L. Andersen, N.D. Vaziri, Expansion
of urease- and uricase-containing: indole- and p-cresol-forming and contraction of
short-chain fatty acid-producing intestinal microbiota in ESRD, Am. J. Nephrol. 39
(2014) 230–237.
[21] S. Jiang, S. Xie, D. Lv, Y. Zhang, J. Deng, L. Zeng, Y. Chen, A reduction in the
butyrate producing species Roseburia spp. and Faecalibacterium prausnitzii is as-
sociated with chronic kidney disease progression, Antonie Van Leeuwenhoek 109
(2016) 1389–1396.
[22] R. Poesen, K. Windey, E. Neven, D. Kuypers, P.V. de, P. Augustijns, P. D'Haese,
P. Evenepoel, K. Verbeke, B. Meijers, The inﬂuence of CKD on colonic microbial
metabolism, J. Am. Soc. Nephrol. 27 (2016) 1389–1399.
[23] E. Mishima, S. Fukuda, C. Mukawa, A. Yuri, Y. Kanemitsu, Y. Matsumoto,
Y. Akiyama, N.N. Fukuda, H. Tsukamoto, K. Asaji, H. Shima, K. Kikuchi, C. Suzuki,
T. Suzuki, Y. Tomioka, T. Soga, S. Ito, T. Abe, Evaluation of the impact of gut
microbiota on uremic solute accumulation by a CE-TOFMS-based metabolomics
approach, Kidney Int. 92 (2017) 634–645.
[24] B. Bammens, K. Verbeke, Y. Vanrenterghem, P. Evenepoel, Evidence for impaired
assimilation of protein in chronic renal failure, Kidney Int. 64 (2003) 2196–2203.
[25] M.M. France, J.R. Turner, The mucosal barrier at a glance, J. Cell Sci. 130 (2017)
307–314.
[26] L.L. Wu, W.H. Peng, W.T. Kuo, C.Y. Huang, Y.H. Ni, K.S. Lu, L.C. Yu, J.R. Turner,
Commensal bacterial endocytosis in epithelial cells is dependent on myosin light
chain kinase-activated brush border fanning by interferon-gamma, Am. J. Pathol.
184 (2014) 2260–2274.
[27] M. Magnusson, K.E. Magnusson, T. Sundqvist, T. Denneberg, Impaired intestinal
barrier function measured by diﬀerently sized polyethylene glycols in patients with
chronic renal failure, Gut 32 (1991) 754–759.
[28] N.D. Vaziri, J. Yuan, A. Rahimi, Z. Ni, H. Said, V.S. Subramanian, Disintegration of
colonic epithelial tight junction in uremia: a likely cause of CKD-associated in-
ﬂammation, Nephrol. Dial. Transplant. 27 (2012) 2686–2693.
[29] B.O. Schroeder, G.M.H. Birchenough, M. Stahlman, L. Arike, M.E.V. Johansson,
G.C. Hansson, F. Backhed, Biﬁdobacteria or ﬁber protects against diet-induced
microbiota-mediated colonic mucus deterioration, Cell Host Microbe 23 (2018)
27–40.
[30] N.D. Vaziri, N. Goshtasbi, J. Yuan, S. Jellbauer, H. Moradi, M. Raﬀatellu,
K. Kalantar-Zadeh, Uremic plasma impairs barrier function and depletes the tight
junction protein constituents of intestinal epithelium, Am. J. Nephrol. 36 (2012)
438–443.
[31] A. Krack, R. Sharma, H.R. Figulla, S.D. Anker, The importance of the gastro-
intestinal system in the pathogenesis of heart failure, Eur. Heart J. 26 (2005)
2368–2374.
[32] B.K. Meijers, L.H. de, B. Bammens, K. Verbeke, Y. Vanrenterghem, P. Evenepoel, p-
Cresyl sulfate and indoxyl sulfate in hemodialysis patients, Clin. J. Am. Soc.
Nephrol. 4 (2009) 1932–1938.
[33] B.K. Meijers, K. Claes, B. Bammens, L.H. de, L. Viaene, K. Verbeke, D. Kuypers,
Y. Vanrenterghem, P. Evenepoel, p-Cresol and cardiovascular risk in mild-to-mod-
erate kidney disease, Clin. J. Am. Soc. Nephrol. 5 (2010) 1182–1189.
[34] F.C. Barreto, D.V. Barreto, S. Liabeuf, N. Meert, G. Glorieux, M. Temmar,
G. Choukroun, R. Vanholder, Z.A. Massy, Serum indoxyl sulfate is associated with
vascular disease and mortality in chronic kidney disease patients, Clin. J. Am. Soc.
Nephrol. 4 (2009) 1551–1558.
[35] R. Poesen, L. Viaene, K. Verbeke, K. Claes, B. Bammens, B. Sprangers, M. Naesens,
Y. Vanrenterghem, D. Kuypers, P. Evenepoel, B. Meijers, Renal clearance and in-
testinal generation of p-Cresyl sulfate and indoxyl sulfate in CKD, Clin. J. Am. Soc.
Nephrol. 8 (2013) 1508–1514.
[36] L. Viaene, L. Thijs, Y. Jin, Y. Liu, Y. Gu, B. Meijers, K. Claes, J. Staessen,
P. Evenepoel, Heritability and clinical determinants of serum indoxyl sulfate and p-
cresyl sulfate, candidate biomarkers of the human microbiome enterotype, PLoS
One 9 (2014) e79682.
[37] R. Vanholder, E. Schepers, A. Pletinck, E.V. Nagler, G. Glorieux, The uremic toxicity
of indoxyl sulfate and p-cresyl sulfate: a systematic review, J. Am. Soc. Nephrol. 25
(2014) 1897–1907.
[38] L. Koppe, N.J. Pillon, R.E. Vella, M.L. Croze, C.C. Pelletier, S. Chambert, Z. Massy,
G. Glorieux, R. Vanholder, Y. Dugenet, H.A. Soula, D. Fouque, C.O. Soulage, p-
Cresyl sulfate promotes insulin resistance associated with CKD, J. Am. Soc. Nephrol.
24 (2013) 88–99.
[39] G. Muteliefu, H. Shimizu, A. Enomoto, F. Nishijima, M. Takahashi, T. Niwa, Indoxyl
sulfate promotes vascular smooth muscle cell senescence with upregulation of p53,
p21, and prelamin A through oxidative stress, Am. J. Physiol. Cell Physiol. 303
(2012) C126–C134.
[40] C.Y. Sun, S.C. Chang, M.S. Wu, Suppression of Klotho expression by protein-bound
uremic toxins is associated with increased DNA methyltransferase expression and
DNA hypermethylation, Kidney Int. 81 (2012) 640–650.
[41] C.Y. Sun, S.C. Chang, M.S. Wu, Uremic toxins induce kidney ﬁbrosis by activating
intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesench-
ymal transition, PLoS One 7 (2012) e34026.
[42] B.K. Meijers, S. Van kerckhoven, k. Verbeke, W. Dehaen, Y. Vanrenterghem,
M.F. Hoylaerts, P. Evenepoel, The uremic retention solute p-cresyl sulfate and
markers of endothelial damage, Am. J. Kidney Dis. 54 (2009) 891–901.
[43] T. Niwa, H. Shimizu, Indoxyl sulfate induces nephrovascular senescence, J. Ren.
Nutr. 22 (2012) 102–106.
[44] E. Schepers, N. Meert, G. Glorieux, J. Goeman, J. Van der Eycken, R. Vanholder, P-
cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free
radical production, Nephrol. Dial. Transplant. 22 (2007) 592–596.
[45] L. Viaene, P. Evenepoel, B. Meijers, D. Vanderschueren, L. Overbergh, C. Mathieu,
Uremia suppresses immune signal-induced CYP27B1 expression in human mono-
cytes, Am. J. Nephrol. 36 (2012) 497–508.
[46] H.J. Hsu, C.H. Yen, I.W. Wu, K.H. Hsu, C.K. Chen, C.Y. Sun, C.C. Chou, C.Y. Chen,
C.J. Tsai, M.S. Wu, C.C. Lee, The association of uremic toxins and inﬂammation in
hemodialysis patients, PLoS One 9 (2018) 2014–e102691.
[47] B.K.I. Meijers, B. Bammens, B. De Moor, K. Verbeke, Y. Vanrenterghem,
P. Evenepoel, Free serum concentrations of p-cresol are independently associated
with cardiovascular disease in hemodialysis, Kindey Int. 73 (2008) 1174–1180.
[48] S. Liabeuf, D.V. Barreto, F.C. Barreto, N. Meert, G. Glorieux, E. Schepers,
M. Temmar, G. Choukroun, R. Vanholder, Z.A. Massy, Free p-cresylsulphate is a
predictor of mortality in patients at diﬀerent stages of chronic kidney disease,
Nephrol. Dial. Transplant. 25 (2010) 1183–1191.
[49] Q.J. Lew, T.H. Jafar, H.W. Koh, A. Jin, K.Y. Chow, J.M. Yuan, W.P. Koh, Red meat
intake and risk of ESRD, J. Am. Soc. Nephrol. 28 (2017) 304–312.
[50] M. Bugaut, Occurrence, absorption and metabolism of short chain fatty acids in the
digestive tract of mammals, Comp. Biochem. Physiol. B 86 (1987) 439–472.
[51] J.L. Pluznick, D.J. Zou, X. Zhang, Q. Yan, D.J. Rodriguez-Gil, C. Eisner, E. Wells,
C.A. Greer, T. Wang, S. Firestein, J. Schnermann, M.J. Caplan, Functional expres-
sion of the olfactory signaling system in the kidney, Proc. Natl. Acad. Sci. U. S. A.
106 (2009) 2059–2064.
[52] J. Gilissen, F. Jouret, B. Pirotte, J. Hanson, Insight into SUCNR1 (GPR91) structure
and function, Pharmacol. Ther. 159 (2016) 56–65.
[53] F.V. Mortensen, H. Nielsen, M.J. Mulvany, I. Hessov, Short chain fatty acids dilate
isolated human colonic resistance arteries, Gut 31 (1990) 1391–1394.
[54] N. Natarajan, D. Hori, S. Flavahan, J. Steppan, N.A. Flavahan, D.E. Berkowitz,
B. Meijers et al. Pharmacological Research 133 (2018) 101–107
106
J.L. Pluznick, Microbial short chain fatty acid metabolites lower blood pressure via
endothelial G protein-coupled receptor 41, Physiol. Genomics 48 (2016) 826–834.
[55] C.W. Nutting, S. Islam, J.T. Daugirdas, Vasorelaxant eﬀects of short chain fatty acid
salts in rat caudal artery, Am. J. Physiol. 261 (1991) H561–H567.
[56] J. Peti-Peterdi, B.K. Kishore, J.L. Pluznick, Regulation of vascular and renal function
by metabolite receptors, Annu. Rev. Physiol. 78 (2016) 391–414.
[57] J.H. Robben, R.A. Fenton, S.L. Vargas, H. Schweer, J. Peti-Peterdi, P.M. Deen,
G. Milligan, Localization of the succinate receptor in the distal nephron and its
signaling in polarized MDCK cells, Kidney Int. 76 (2009) 1258–1267.
[58] P. Rajkumar, W.H. Aisenberg, O.W. Acres, R.J. Protzko, J.L. Pluznick, Identiﬁcation
and characterization of novel renal sensory receptors, PLoS One 9 (2014) e111053.
[59] X. Liu, F. Gu, L. Jiang, F. Chen, F. Li, Expression of bitter taste receptor Tas2r105 in
mouse kidney, Biochem. Biophys. Res. Commun. 458 (2015) 733–738.
[60] F.Z. Marques, C.R. Mackay, D.M. Kaye, Beyond gut feelings: how the gut microbiota
regulates blood pressure, Nat. Rev. Cardiol. 15 (2018) 20–32.
[61] J.L. Pluznick, Microbial short-chain fatty acids and blood pressure regulation, Curr.
Hypertens. Rep. 19 (2017) 25.
[62] A.J. Brown, S.M. Goldsworthy, A.A. Barnes, M.M. Eilert, L. Tcheang, D. Daniels,
A.I. Muir, M.J. Wigglesworth, I. Kinghorn, N.J. Fraser, N.B. Pike, J.C. Strum,
K.M. Steplewski, P.R. Murdock, J.C. Holder, F.H. Marshall, P.G. Szekeres, S. Wilson,
D.M. Ignar, S.M. Foord, A. Wise, S.J. Dowell, The Orphan G protein-coupled re-
ceptors GPR41 and GPR43 are activated by propionate and other short chain car-
boxylic acids, J. Biol. Chem. 278 (2003) 11312–11319.
[63] J.L. Pluznick, R.J. Protzko, H. Gevorgyan, Z. Peterlin, A. Sipos, J. Han, I. Brunet,
L.X. Wan, F. Rey, T. Wang, S.J. Firestein, M. Yanagisawa, J.I. Gordon, A. Eichmann,
J. Peti-Peterdi, M.J. Caplan, Olfactory receptor responding to gut microbiota-de-
rived signals plays a role in renin secretion and blood pressure regulation, Proc.
Natl. Acad. Sci. U. S. A. 110 (2013) 4410–4415.
[64] J.L. Pluznick, Renal and cardiovascular sensory receptors and blood pressure reg-
ulation, Am. J. Physiol. Renal Physiol. 305 (2013) F439–F444.
[65] S.P. Whelton, A.D. Hyre, B. Pedersen, Y. Yi, P.K. Whelton, J. He, Eﬀect of dietary
ﬁber intake on blood pressure: a meta-analysis of randomized controlled clinical
trials, J. Hypertens. 23 (2005) 475–481.
[66] E. Holmes, R.L. Loo, J. Stamler, M. Bictash, I.K. Yap, Q. Chan, T. Ebbels, I.M. De,
I.J. Brown, K.A. Veselkov, M.L. Daviglus, H. Kesteloot, H. Ueshima, L. Zhao,
J.K. Nicholson, P. Elliott, Human metabolic phenotype diversity and its association
with diet and blood pressure, Nature 453 (2008) 396–400.
[67] S. Khalesi, J. Sun, N. Buys, R. Jayasinghe, Eﬀect of probiotics on blood pressure: a
systematic review and meta-analysis of randomized controlled trials, Hypertension
64 (2014) 897–903.
[68] M.D. Pagel, S. Ahmad, J.E. Vizzo, B.H. Scribner, Acetate and bicarbonate ﬂuctua-
tions and acetate intolerance during dialysis, Kidney Int. 21 (1982) 513–518.
[69] M.K. Raizada, B. Joe, N.S. Bryan, E.B. Chang, F.E. Dewhirst, G.G. Borisy, Z.S. Galis,
W. Henderson, P.A. Jose, C.J. Ketchum, J.W. Lampe, C.J. Pepine, J.L. Pluznick,
D. Raj, D.R. Seals, R.A. Gioscia-Ryan, W.H.W. Tang, Y.S. Oh, Report of the national
heart, lung, and blood institute working group on the role of microbiota in blood
pressure regulation: current status and future directions, Hypertension (2017)
(ePUB ahead of publication).
[70] T. Yang, M.M. Santisteban, V. Rodriguez, E. Li, N. Ahmari, J.M. Carvajal, M. Zadeh,
M. Gong, Y. Qi, J. Zubcevic, B. Sahay, C.J. Pepine, M.K. Raizada,
M. Mohamadzadeh, Gut dysbiosis is linked to hypertension, Hypertension 65
(2015) 1331–1340.
[71] K.M. Maslowski, A.T. Vieira, A. Ng, J. Kranich, F. Sierro, D. Yu, H.C. Schilter,
M.S. Rolph, F. Mackay, D. Artis, R.J. Xavier, M.M. Teixeira, C.R. Mackay,
Regulation of inﬂammatory responses by gut microbiota and chemoattractant re-
ceptor GPR43, Nature 461 (2009) 1282–1286.
[72] C.W. McIntyre, L.E. Harrison, M.T. Eldehni, H.J. Jeﬀeries, C.C. Szeto, S.G. John,
M.K. Sigrist, J.O. Burton, D. Hothi, S. Korsheed, P.J. Owen, K.B. Lai, P.K. Li,
Circulating endotoxemia: a novel factor in systemic inﬂammation and cardiovas-
cular disease in chronic kidney disease, Clin. J. Am. Soc. Nephrol. 6 (2011)
133–141.
[73] E. Ritz, Intestinal-renal syndrome: mirage or reality? Blood Purif. 31 (2011) 70–76.
[74] P. Kotanko, M. Carter, N.W. Levin, Intestinal bacterial microﬂora–a potential source
of chronic inﬂammation in patients with chronic kidney disease, Nephrol. Dial.
Transplant. 21 (2006) 2057–2060.
[75] E. Metchnikoﬀ, The Prolongation of Life – Optimistic Studies, (1908).
[76] N. Thevaranjan, A. Puchta, C. Schulz, A. Naidoo, J.C. Szamosi, C.P. Verschoor,
D. Loukov, L.P. Schenck, J. Jury, K.P. Foley, J.D. Schertzer, M.J. Larche,
D.J. Davidson, E.F. Verdu, M.G. Surette, D.M.E. Bowdish, Age-associated microbial
dysbiosis promotes intestinal permeability, systemic inﬂammation, and macro-
phage dysfunction, Cell Host Microbe 21 (2017) 455–466.
[77] M. Bossola, M. Sanguinetti, D. Scribano, C. Zuppi, S. Giungi, G. Luciani, R. Torelli,
B. Posteraro, G. Fadda, L. Tazza, Circulating bacterial-derived DNA fragments and
markers of inﬂammation in chronic hemodialysis patients, Clin. J. Am. Soc.
Nephrol. 4 (2009) 379–385.
[78] J.J. Carrero, P. Stenvinkel, Inﬂammation in end-stage renal disease–what have we
learned in 10 years? Semin. Dial. 23 (2010) 498–509.
[79] D.S. Raj, J.J. Carrero, V.O. Shah, A.R. Qureshi, P. Barany, O. Heimburger,
B. Lindholm, J. Ferguson, P.L. Moseley, P. Stenvinkel, Soluble CD14 levels, inter-
leukin 6, and mortality among prevalent hemodialysis patients, Am. J. Kidney Dis.
54 (2009) 1072–1080.
[80] D.S. Raj, V.O. Shah, M. Rambod, C.P. Kovesdy, K. Kalantar-Zadeh, Association of
soluble endotoxin receptor CD14 and mortality among patients undergoing hemo-
dialysis, Am. J. Kidney Dis. 54 (2009) 1062–1071.
[81] R. Poesen, A. Ramezani, K. Claes, P. Augustijns, D. Kuypers, I.R. Barrows,
J. Muralidharan, P. Evenepoel, B. Meijers, D.S. Raj, Associations of soluble CD14
and endotoxin with mortality, cardiovascular disease, and progression of kidney
disease among patients with CKD, Clin. J. Am. Soc. Nephrol. 10 (2015) 1525–1533.
[82] R. Ross, Atherosclerosis–an inﬂammatory disease, N. Engl. J. Med. 340 (1999)
115–126.
[83] P.M. Ridker, B.M. Everett, T. Thuren, J.G. MacFadyen, W.H. Chang, C. Ballantyne,
F. Fonseca, J. Nicolau, W. Koenig, S.D. Anker, J.J.P. Kastelein, J.H. Cornel, P. Pais,
D. Pella, J. Genest, R. Cifkova, A. Lorenzatti, T. Forster, Z. Kobalava, L. Vida-Simiti,
M. Flather, H. Shimokawa, H. Ogawa, M. Dellborg, P.R.F. Rossi, R.P.T. Troquay,
P. Libby, R.J. Glynn, Antiinﬂammatory therapy with canakinumab for athero-
sclerotic disease, N. Engl. J. Med. 377 (2017) 1119–1131.
[84] S. Lekawanvijit, A.R. Kompa, H. Krum, Protein-bound uremic toxins: a long over-
looked culprit in cardiorenal syndrome, Am. J. Physiol. Renal Physiol. 311 (2016)
F52–F62.
[85] R. Poesen, B. Meijers, P. Evenepoel, The colon: an overlooked site for therapeutics
in dialysis patients, Semin. Dial. 26 (2013) 323–332.
[86] A. Ramezani, D.S. Raj, The gut microbiome, kidney disease, and targeted inter-
ventions, J. Am. Soc. Nephrol. 25 (2014) 657–670.
[87] N.D. Vaziri, J. Yuan, K. Norris, Role of urea in intestinal barrier dysfunction and
disruption of epithelial tight junction in chronic kidney disease, Am. J. Nephrol. 37
(2013) 1–6.
[88] G. Schulman, T. Berl, G.J. Beck, G. Remuzzi, E. Ritz, K. Arita, A. Kato, M. Shimizu,
Randomized placebo-controlled EPPIC trials of AST-120 in CKD, J. Am. Soc.
Nephrol. 26 (2015) 1732–1746.
[89] V.M. Brandenburg, G. Schlieper, N. Heussen, S. Holzmann, B. Busch, P. Evenepoel,
R. Vanholder, B. Meijers, N. Meert, W.J. Fassbender, J. Floege, W. Jahnen-Dechent,
M. Ketteler, Serological cardiovascular and mortality risk predictors in dialysis
patients receiving sevelamer: a prospective study, Nephrol. Dial. Transplant. 25
(2010) 2672–2679.
[90] B. Guida, M. Cataldi, E. Riccio, L. Grumetto, A. Pota, S. Borrelli, A. Memoli,
F. Barbato, G. Argentino, G. Salerno, B. Memoli, Plasma p-cresol lowering eﬀect of
sevelamer in peritoneal dialysis patients: evidence from a Cross-Sectional
Observational Study, PLoS One 8 (2018) 2013–e73558.
[91] R. Masereeuw, J. Löwenstein, T. Toyohara, A. Sparreboom, D. Sweet, R. Mutsaers,
The kidney and uremic toxin removal: glomerulus or tubulus? Semin. Nephrol.
(2016) 2014.
[92] T.W. Meyer, E.C. Leeper, D.W. Bartlett, T.A. Depner, Y.Z. Lit, C.R. Robertson,
T.H. Hostetter, Increasing dialysate ﬂow and dialyzer mass transfer area coeﬃcient
to increase the clearance of protein-bound solutes, J. Am. Soc. Nephrol. 15 (2004)
1927–1935.
[93] B.K.I. Meijers, B. Bammens, K. Verbeke, P. Evenepoel, A review of albumin binding
in CKD, Am. J. Kidney Dis. 51 (2008) 839–850.
[94] T.W. Meyer, J.W. Peattie, J.D. Miller, D.C. Dinh, N.S. Recht, J.L. Walther,
T.H. Hostetter, Increasing the clearance of protein-bound solutes by addition of a
sorbent to the dialysate, J. Am. Soc. Nephrol. 18 (2007) 868–874.
[95] B.K.I. Meijers, V. Weber, B. Bammens, W. Dehaen, K. Verbeke, D. Falkenhagen,
P. Evenepoel, Removal of the uremic retention solute p-cresol using fractionated
plasma separation and adsorption, Artif. Org. 32 (2008) 214–219.
B. Meijers et al. Pharmacological Research 133 (2018) 101–107
107
